



## **Cohere Medicare Advantage Policy – Hip Arthroplasty**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 3.1  
**Revision Date:** March 21, 2025

This policy was reviewed by AAOS prior to publication.

# Important Notices

## Notices & Disclaimers:

**GUIDELINES ARE SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION-MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine the medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third-party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice. This policy may be superseded by existing and applicable Centers for Medicare & Medicaid Services (CMS) statutes.

©2025 Cohere Health, Inc. All Rights Reserved.

---

## Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

---

## Guideline Information:

**Specialty Area:** Disorders of the Musculoskeletal System

**Guideline Name:** Cohere Medicare Advantage Policy - Hip Arthroplasty

**Date of last literature review:** 1/14/2025

**Document last updated:** 3/21/2025

**Type:**  Adult (18+ yo) |  Pediatric (0-17yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
Table of Contents	3
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Hip Arthroplasty</b>	<b>4</b>
Benefit Category	4
Related CMS Documents	4
Recommended Clinical Approach	4
Evaluation of Clinical Benefits and Potential Harms	5
Medical Necessity Criteria	6
Indications	6
Non-Indications	9
Level of Care Criteria	9
Procedure Codes (CPT/HCPCS)	9
<b>Medical Evidence</b>	<b>11</b>
<b>References</b>	<b>13</b>
<b>Clinical Guideline Revision History/Information</b>	<b>18</b>

# Medical Necessity Criteria

**Service: Hip Arthroplasty**

## **Benefit Category**

Not applicable.

## **Related CMS Documents**

Please refer to the [CMS Medicare Coverage Database](#) for the most current applicable CMS National Coverage.<sup>1-7</sup>

- [Local Coverage Determination. Total Joint Arthroplasty \(L36039\)](#)
- [Local Coverage Determination. Major Joint Replacement \(Hip and Knee\). \(L33618\)](#)
- [Local Coverage Determination. Total Joint Arthroplasty. \(L33456\)](#)
- [Local Coverage Determination. Lower Extremity Major Joint Replacement \(Hip and Knee\). \(L36007\)](#)
- [Local Coverage Determination. Total Joint Arthroplasty. \(L39911\)](#)
- [Local Coverage Determination. Total Hip Arthroplasty. \(L34163\)](#)
- [Local Coverage Determination. Total Hip Arthroplasty. \(L36573\)](#)

## **Recommended Clinical Approach**

Hip arthroplasty is a surgical intervention to reduce hip pain and restore function by replacing a damaged or diseased hip joint with an artificial prosthesis. It is appropriate in patients with persistent, disabling symptoms despite non-surgical management. Partial hip replacement (hemiarthroplasty) may be indicated when only the femoral side of the hip joint is damaged. Total hip arthroplasty replaces the ball and socket parts of the hip joint in cases of severe damage. If a patient has had a prior hip arthroplasty and presents with pain that may be due to infection, recurrent hip dislocation, aseptic loosening, excessive wear, mechanical failure, or fracture, then revision surgery may be indicated. Hip arthroplasty is generally well-tolerated with appropriate patient selection and confers an improved quality of life.<sup>8-11</sup>

## **Evaluation of Clinical Benefits and Potential Harms**

Cohere Health uses the criteria below to ensure consistency in reviewing the conditions to be met for coverage of hip arthroplasty procedures. This process helps to prevent both incorrect denials and inappropriate approvals of medically necessary services. Specifically, limiting incorrect approvals reduces the risks associated with unnecessary procedures, such as complications from surgery, adverse reactions, and infection.

**The potential clinical harms** of using these criteria may include:

- Adverse effects from delayed or denied treatment, such as increased pain and decreased mobility, can worsen patient outcomes. Hip replacement surgery has been shown to be a cost-effective treatment when nonsurgical means do not offer pain relief.<sup>8</sup> Therefore, surgical delay may worsen their outcomes with ongoing persistent pain that could result in opioid dependence, emergency room visits, increased healthcare utilization, and decreased quality of life.<sup>8</sup>
- Risks with inappropriate surgical procedures include infection, bleeding requiring a transfusion, injury to neurovascular structures, anesthetic risk, and need for repeat or additional procedures due to implant failure, periprosthetic fracture, and ongoing pain. The average time to revision of a primary total hip arthroplasty is 8.51 years.<sup>12</sup> If a patient has an inappropriate initial total hip arthroplasty, this can lead to additional surgeries; therefore, careful patient selection is in the patient's best interest.
- Increased healthcare costs and complications from the inappropriate use of emergency services and additional treatments.

**The potential clinical benefits** of using these criteria include:

- Improved patient outcomes by ensuring timely and appropriate access to hip arthroplasty. In general, careful patient selection confers the best outcomes and can prevent revision surgery.<sup>8,12</sup> The most common indications for hip arthroplasty include pain that cannot be controlled by conservative therapy, functional deficit, and radiologic changes with evidence of joint degeneration.
- Reduction in complications or adverse effects from unnecessary procedures. Given the high rate of revision surgery, with the average time to revision of a primary total hip arthroplasty of only 8.51 years, it is crucial to avoid unnecessary surgery, as in the future, it may result in additional invasive management.<sup>12</sup>

- Appropriate management of orthopaedic trauma. Hip arthroplasty is indicated for adults with a femoral neck fracture. Patients with a hip fracture who have surgery performed within 24 to 48 hours of admission have better outcomes.<sup>9</sup> This criteria allows approval for patients with an acute fracture of the femoral head or neck without requiring any additional treatment in order to expedite their treatment.
- Enhanced overall patient satisfaction with the healthcare experience and return of function. Positive patient-reported outcomes include reduced pain, improved function, and increased quality of life for individuals.

This policy includes provisions for expedited reviews and flexibility in urgent cases to mitigate risks of delayed access. Evidence-based criteria are employed to prevent inappropriate denials, ensuring that patients receive medically necessary care. The criteria aim to balance the need for effective treatment with the minimization of potential harms, providing numerous clinical benefits in helping avoid unnecessary complications from inappropriate care.

In addition, the use of these criteria is likely to decrease inappropriate denials by creating a consistent set of review criteria, thereby supporting optimal patient outcomes and efficient healthcare utilization.

## Medical Necessity Criteria

### Indications

→ **Hip arthroplasty** is considered appropriate if **ANY** of the following is **TRUE**:

- ◆ The procedure is a **total hip arthroplasty** and **ALL** of the following are **TRUE**:
  - **ANY** of the following is true:
    - If a bilateral total hip arthroplasty is performed, documentation of advanced joint disease must be present in both hips<sup>14-7</sup>; **OR**
    - Not applicable (i.e., single-hip arthroplasty); **AND**
  - **ANY** of the following is **TRUE**:
    - Advanced joint disease and **ALL** of the following<sup>14-7</sup>:
      - ◆ Pain or functional disability<sup>14-7</sup>; **AND**

- ◆ Failure of conservative management for greater than 3 months, including **ANY** of the following<sup>1,4-7</sup>:
  - Rest or activity restriction as is reasonable<sup>2,4</sup>; **OR**
  - Anti-inflammatory medications, non-opioid analgesics, or prescription medications (e.g., oral steroids, neuropathic pain medications) if not contraindicated<sup>2,4</sup>; **OR**
  - Flexibility and muscle-strengthening exercises<sup>2,4</sup>; **OR**
  - Physical therapy or physician-directed exercise program<sup>2,4</sup>; **OR**
  - Assistive device use<sup>2,4</sup>; **OR**
  - **ANY** of the following:
    - Corticosteroid injection if medically appropriate<sup>2,4</sup>; **OR**
    - Documentation that injection is contraindicated<sup>2,4</sup>; **OR**
  - Weight reduction as appropriate<sup>2,4</sup>; **OR**
  - Documentation indicating that conservative, non-surgical management would be ineffective or counterproductive, including **ANY** of the following<sup>2,4</sup>:
    - Intractable pain or significant disabling interference with activities of daily living (ADLs); **OR**
    - Bone-on-bone articulation; **OR**
    - Severe deformity; **OR**
    - Failure of a previous osteotomy; **OR**
    - Malignancy of hip joint or adjacent soft tissues; **OR**
    - Avascular necrosis of the hip; **AND**
- ◆ **ANY** of the following:
  - Radiographic-supported evidence<sup>1-7</sup>; **OR**
  - When conventional radiography is not adequate, magnetic resonance imaging

(MRI) or computed tomography (CT) (in situations when MRI is non-diagnostic or not able to be performed)-supported evidence (i.e., subchondral cysts, subchondral sclerosis, periarticular osteophytes, joint subluxation, joint space narrowing, avascular necrosis)<sup>1-7</sup>; **OR**

- Malignancy of the joint involving the bones or soft tissues of the pelvis or proximal femur<sup>4,6-7</sup>; **OR**
- Avascular necrosis<sup>4,6-7</sup>; **OR**
- Femoral neck fracture<sup>4,6-7</sup>; **OR**
- Non-union or malunion of the femoral neck<sup>4,6-7</sup>; **OR**
- Acute fracture of the femoral head or neck that is untreatable with open reduction and internal fixation (ORIF)<sup>4,6-7</sup>; **OR**
- Acetabular fracture<sup>4,6-7</sup>; **OR**
- Nonunion or failure of prior hip fracture surgery<sup>4,6-7</sup>; **OR**
- Malunion of acetabular or proximal femur fracture<sup>4,6-7</sup>; **OR**

◆ The procedure is a **partial hip arthroplasty (hip hemiarthroplasty)** and **ANY** of the following is **TRUE**:

- Displaced femoral head or neck fracture<sup>9,13-14</sup>; **OR**
- Acute fracture of the femoral head or neck that is untreatable with open reduction and internal fixation (ORIF)<sup>9</sup>; **OR**
- Fracture dislocation of the hip untreatable with ORIF<sup>8,9</sup>; **OR**
- Avascular necrosis of the femoral head<sup>8,9</sup>; **OR**
- Non-union fracture of the femoral neck<sup>8,9</sup>; **OR**
- Degenerative arthritis of the femoral head only in which the acetabulum does not need replacement<sup>8,9</sup>; **OR**

◆ The procedure is a **replacement/revision of prior arthroplasty** and **ANY** of the following is **TRUE**:

- Surgical management of total joint infection<sup>1,4-7</sup>; **OR**
- Instability<sup>1,4-7</sup>; **OR**
- Loosening of the prosthesis<sup>1,4-7</sup>; **OR**
- Failure of the prosthesis<sup>1,4-7</sup>; **OR**
- Periprosthetic fracture<sup>1,4-7</sup>; **OR**
- Recurrent or irreducible hip dislocation<sup>1,4-7</sup>; **OR**
- Tissue or systemic reaction to implant<sup>1,4-7</sup>; **OR**

- Clinically significant leg-length inequality not amenable to conservative management<sup>1,4-7</sup>; **OR**
- Progressive or substantial bone loss<sup>1,4-7</sup>; **OR**
- Bearing surface wear resulting in symptomatic synovitis<sup>1,4-7</sup>; **OR**
- Clinically significant audible noise.<sup>1,4-7</sup>

## Non-Indications

→ **Hip Arthroplasty** is not considered appropriate if **ANY** of the following is **TRUE**<sup>4-9,11</sup>:

- ◆ Active infection of the hip joint<sup>4-7</sup>; **OR**
- ◆ Active systemic bacteremia<sup>4-7</sup>; **OR**
- ◆ Active urinary tract or dental infection<sup>4-7</sup>; **OR**
- ◆ Active skin infection (exception of recurrent cutaneous staph infections)<sup>4-7</sup>; **OR**
- ◆ Open wound within the planned surgical site of the hip; **OR**
- ◆ Rapidly progressive neurological disease, unless a concomitant displaced femoral neck fracture is present<sup>4-7</sup>; **OR**
- ◆ Skeletal immaturity<sup>16</sup>; **OR**
- ◆ Neuropathic/neurotrophic arthritis<sup>4-7</sup>; **OR**
- ◆ Absence or relative insufficiency of abductor musculature.<sup>4-7</sup>

## Level of Care Criteria

Inpatient or outpatient.

## Procedure Codes (CPT/HCPCS)

HCPCS/CPT Code	Code Description
26990	Drainage of abscess or blood accumulation in pelvis or hip joint
26991	Incision of infected fluid-filled sac (bursa) of pelvis or hip joint
27030	Incision of hip joint with drainage
27125	Hemiarthroplasty, hip, partial (eg, femoral stem prosthesis, bipolar arthroplasty)
27130	Replacement of thigh bone and hip joint prosthesis
27132	Conversion of previous replacement of thigh bone and hip

	joint prosthesis
27134	Revision of thigh bone and hip joint prosthesis
27137	Revision of hip joint prosthesis
27138	Revision of femoral component of total hip arthroplasty; Revision of femoral component of total hip arthroplasty with allograft
27236	Open treatment of femoral fracture, proximal end, neck, internal fixation or prosthetic replacement
27250	Treatment of hip dislocation
27299	Unlisted procedure, pelvis or hip joint

# Medical Evidence

Published in 2019, the Hip Fracture Evaluation with Alternatives of Total Hip Arthroplasty (HEALTH) trial, an expertise-based randomized controlled trial, enrolled 1495 patients across 10 countries to determine the most appropriate procedure to surgically manage hip fractures in older adults with displaced femoral neck fractures. Patients aged 50 and older underwent either total hip arthroplasty (THA) or hemiarthroplasty. The study team found similar mortality rates, no significant difference in the incidence of secondary procedures between groups, as well as what was ultimately deemed a “clinically unimportant” improvement among THA recipients as compared to hemiarthroplasty recipients. Therefore, the authors felt there to be limited advantages of THA with a higher risk profile in this patient population. This landmark study began to dismantle the traditional dogma of THA as the standard of care for patients of all ages with displaced femoral neck fractures.<sup>13</sup>

A 2021 meta-analysis of 40 studies comprising 3,561,446 hips found several patient-related risk factors that were associated with a higher risk of periprosthetic joint infection (PJI) after THA. High body mass index (BMI), femoral neck fracture, and opioid use conferred a higher risk of PJI. Interestingly, biological female sex, dislocation/dysplasia, and osteoarthritis were protective factors. The authors noted the importance of reducing the risk of PJI and subsequent revision or other invasive management by careful patient selection and optimization of modifiable risk factors.<sup>17</sup>

The American Academy of Orthopaedic Surgeons (AAOS) has published two guidelines pertaining to hip arthroplasty. *Management of Hip Fractures in Older Adults*, adopted in 2021, recommends arthroplasty over fixation for unstable femoral neck fractures.<sup>9</sup> The authors cite a decreased rate of reoperation among arthroplasty patients, though they note no statistical difference in mortality upon composite analysis of the reference studies.<sup>9</sup> *Management of Osteoarthritis of the Hip*, adopted in 2023, provides a robust set of clinical indications for surgical management of osteoarthritis, including hip arthroplasty.<sup>11</sup> The clinical practice guideline supports the use of NSAIDs to relieve pain and facilitate movement. In addition, it endorses careful patient screening and appropriate optimization in order to improve surgical

outcomes.<sup>11</sup> The AAOS has also issued position statements pertaining to hip arthroplasty. Information statement 1047, published in 2016, acknowledges the increased patient safety risks conferred by tobacco use – including pneumonia, impeded healing, surgical site infection, postoperative cardiopulmonary events, and death.<sup>18</sup> The AAOS states that patients who are active smokers may reduce these risks through cessation of smoking prior to surgery; they also note the special role orthopaedic surgeons play in counseling patients on the benefits of reduced or eliminated tobacco use before surgery. Importantly, unconfirmed cessation is not endorsed as a hard stop to surgery; rather, the surgeon’s unique role as an advocate for preoperative smoking cessation is emphasized. Statements 1040 and 1184 discuss the impact of obesity on musculoskeletal conditions.<sup>19,20</sup> Statement 1184 endorses the importance of continued patient–surgeon conversation around the increased surgical risks associated with obesity, including increased complications and rates of hardware failure following hip replacement. Patients with morbid obesity (BMI of 40 or above) are encouraged to participate in a weight loss program, obtain weight reduction resources through their physician, rectify nutritional deficiencies, and consider a delay in surgical treatment if it would facilitate participation in weight loss interventions that may improve surgical outcomes. Statement 1040 reinforces the risks associated with obesity and total joint arthroplasty and encourages adequate patient counseling prior to surgery.

Social determinants of health remain an important area of ongoing orthopaedic surgery research, with recent literature raising questions regarding the healthcare disparities that may be potentiated by care limitations based on obesity and smoking status/nicotine dependence.<sup>21-24</sup> Other ongoing research interrogates the impacts that biological sex, race, and socioeconomic status have on hip arthroplasty utilization and outcomes.<sup>26-30</sup>

## References

1. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Total joint arthroplasty (L36039). Revision Effective Date October 10, 2019. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
2. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Major joint replacement (Hip and Knee) (L33618). Revision Effective Date January 8, 2019. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
3. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Total joint arthroplasty (L33456). Revision Effective Date June 15, 2023. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
4. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Lower Extremity Major Joint Replacement (Hip and Knee) (L36007). Revision Effective Date November 14, 2019. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
5. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Total joint arthroplasty (L39911). Revision Effective Date February 28, 2025. Accessed March 18, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
6. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Total hip arthroplasty (L34163). Revision Effective Date December 1, 2019. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
7. Centers for Medicare and Medicaid Services (CMS). Local coverage determination (LCD): Total hip arthroplasty (L36573). Revision Effective Date December 1, 2019. Accessed January 14, 2025.  
<https://www.cms.gov/medicare-coverage-database/search.aspx>.
8. Harkess JW, Crockarell JR. Arthroplasty of the hip. In: Azar FM, Beaty JH, editors. *Campbell's Operative Orthopaedics*. 14th ed. Philadelphia, PA: Elsevier; 2021:406-484.e12.
9. American Academy of Orthopaedic Surgeons Management of Hip Fractures in Older Adults Evidence-Based Clinical Practice Guideline. <https://www.aaos.org/hipfxcpq> Published 12/03/2021.

10. Gademian MG, Hofstede SN, Vliet Vlieland TP, et al. Indication criteria for total hip or knee arthroplasty in osteoarthritis: A state-of-the-science overview. *BMC Musculoskelet Disord*. 2016;17(1):463. doi: 10.1186/s12891-016-1325-z. PMID: 27829422.
11. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Hip Evidence-Based Clinical Practice Guideline. [aaos.org/oahcpg2](https://www.aaos.org/oahcpg2) Published 12/01/2023.
12. Kelmer G, Stone AH, Turcotte J, et al. Reasons for revision: Primary total hip arthroplasty mechanisms of failure. *J Am Acad Orthop Surg*. 2021;29(2):78-87. doi: 10.5435/JAAOS-D-19-00860. PMID: 32404682.
13. Health Investigators. Total hip arthroplasty or hemiarthroplasty for hip fracture. *NEJM*. 2019;381(23):2199-2208. doi: 10.1056/NEJMoA1906190. PMID: 31557429.
14. Chammout G, Kelly-Pettersson P, Hedbeck CJ, et al. HOPE-Trial: hemiarthroplasty compared with total hip arthroplasty for displaced femoral neck fractures in octogenarians: a randomized controlled trial. *JBJS Open Access*. 2019 Apr 1;4(2):e0059. DOI: 10.2106/JBJS.OA.18.00059
15. Liu KL, Wu WT, Wang JH, et al. When and how do prosthetic hips fail after total hip arthroplasties? A retrospective study. *J Formos Med Assoc*. 2016;115(9):786-793. doi: 10.1016/j.jfma.2015.07.014. PMID: 26272352.
16. Van de Velde SK, Loh B, Donnan L. Total hip arthroplasty in patients 16 years of age or younger. *J Child Orthop*. 2017;11(6):428-433. doi:10.1302/1863-2548.11.170085
17. Ren X, Ling L, Qi L, Liu Z, Zhang W, Yang Z, Wang W, Tu C, Li Z. Patients' risk factors for periprosthetic joint infection in primary total hip arthroplasty: a meta-analysis of 40 studies. *BMC Musculoskeletal Disorders*. 2021 Dec;22:1-7. <https://doi.org/10.1186/s12891-021-04647-1>
18. American Academy of Orthopaedic Surgeons. Information Statement 1047: Tobacco Use and Orthopaedic Surgery. Published February 2016. Accessed January 3, 2025. <https://www.aaos.org/globalassets/about/bylaws-library/information-statements/1047-tobacco-use-and-orthopaedic-surgery-3.pdf>.
19. American Academy of Orthopaedic Surgeons. Information Statement 1040: Obesity and Musculoskeletal Care. Published June 2022. Accessed January 3, 2025. <https://www.aaos.org/globalassets/about/bylaws-library/information-statements/1040-obesity-and-musculoskeletal-care.pdf>.
20. American Academy of Orthopaedic Surgeons. Information Statement 1184: The Impact of Obesity on Bone and Joint Health. Published March 2015. Accessed January 3, 2025. <https://www.aaos.org/contentassets/1cd7f41417ec4dd4b5c4c48532183b96/1184-the-impact-of-obesity-on-bone-and-joint-health1.pdf>.

21. Sabesan VJ, Rankin KA, Nelson C. Movement is life—optimizing patient access to total joint arthroplasty: Obesity disparities. *JAAOS*. 2022 Nov 1;30(21):1028–35.
22. O'connor MI, Burney III D, Jones LC. Movement Is Life—Optimizing Patient Access to Total Joint Arthroplasty: Smoking Cessation Disparities. *JAAOS*. 2022 Nov 15;30(22):1055–8.
23. Connors JP, Strecker S, Nagarkatti D, Carangelo RJ, Witmer D. Increasing Body Mass Index Not Associated With Worse Patient-Reported Outcomes After Primary THA or TKA. *JAAOS*. 2022 May 13:10–5435.
24. Hamilton WG. No Smoking Allowed: Is the Operating Room the Next Place That Smoking Patients Undergoing Total Joint Arthroplasty Will Be Banned?: Commentary on an article by Eric H. Tischler, BA, et al.: "Smoking Increases the Rate of Reoperation for Infection within 90 Days After Primary Total Joint Arthroplasty". *JBJS*. 2017 Feb 15;99(4):e17.
25. Zalikha AK, Almsaddi T, Nham F, Hussein IH, El-Othmani MM. Comorbidity, Racial, and Socioeconomic Disparities in Total Knee and Hip Arthroplasty at High Versus Low-Volume Centers. *JAAOS*. 2023 Mar 1;31(5):e264–70.
26. Woolley KA, Chi H, Allahabadi S, et al. Sex-based differences in the utilization of shoulder, hip, and knee arthroplasty. *JAAOS Global Research & Reviews*. 2023 Aug 1;7(8):e23.
27. Chen A, Paxton L, Zheng X, Peat R, Mao J, Liebeskind A, Gressler LE, Marinac-Dabic D, Devlin V, Cornelison T, Sedrakyan A. Association of sex with risk of 2-year revision among patients undergoing total hip arthroplasty. *JAMA network open*. 2021 Jun 1;4(6):e2110687–.
28. Dubin J, Bains S, Ihekweazu UN, Mont MA, Delanois R. Social Determinants of Health in Total Joint Arthroplasty: Income. *The Journal of arthroplasty*. 2024 Mar 14.
29. Delanois RE, Sax OC, Wilkie WA, Douglas SJ, Mohamed NS, Mont MA. Social determinants of health in total hip arthroplasty: are they associated with costs, lengths of stay, and patient reported outcomes?. *The Journal of arthroplasty*. 2022 Jul 1;37(7):S422–7.
30. Dubin J, Bains S, Ihekweazu UN, Mont MA, Delanois R. Social determinants of health in total joint arthroplasty: race. *The Journal of arthroplasty*. 2024 Jun 1;39(6):1394–6.
31. Ravi B, Pincus D, Khan H, Wasserstein D, Jenkinson R, Kreder HJ. Comparing complications and costs of total hip arthroplasty and

- hemiarthroplasty for femoral neck fractures: a propensity score-matched, population-based study. *JBJS*. 2019 Apr 3;101(7):572-9. DOI: 10.2106/JBJS.18.00539
32. Houdek MT, Watts CD, Wyles CC, Trousdale RT, Milbrandt TA, Taunton MJ. Total hip arthroplasty in patients with cerebral palsy: a cohort study matched to patients with osteoarthritis. *JBJS*. 2017 Mar 15;99(6):488-93. DOI: 10.2106/JBJS.16.00528
33. Mundi R, Pincus D, Schemitsch E, Ekhtiari S, Paterson JM, Chaudhry H, Leis JA, Redelmeier DA, Ravi B. Association between periprosthetic joint infection and mortality following primary total hip arthroplasty. *JBJS*. 2024 Sep 4;106(17):1546-52. DOI: 10.2106/JBJS.23.01160
34. Ocokoljic A, Krivec L, Alimy AR, Simon A, Strahl A, Beil FT, Rolvien T. Short-term prediction of clinical and radiographic contralateral hip osteoarthritis after index total hip arthroplasty. *Archives of Orthopaedic and Trauma Surgery*. 2024 Dec;145(1):1-0. <https://doi.org/10.1007/s00402-024-05615-9>
35. Zampogna B, Ferrini A, Zampoli A, Talesa GR, Giusti S, Papalia GF, Vorini F, Papalia R. Total hip arthroplasty in patients under 35 years: a systematic review of the last 2 decades studies. *Hip International*. 2025 Jan;35(1):92-101.
36. Fassihi SC, Lee R, Quan T, Tran AA, Stake SN, Unger AS. Total hip arthroplasty in patients with sickle cell disease: a comprehensive systematic review. *The Journal of Arthroplasty*. 2020 Aug 1;35(8):2286-95. <https://doi.org/10.1016/j.arth.2020.04.014>
37. McCormick KL, Mastroianni MA, Kolodychuk NL, Herndon CL, Shah RP, Cooper HJ, Sarpong NO. Complications and Survivorship After Aseptic Revision Total Hip Arthroplasty: Is There a Difference by Surgical Approach?. *The Journal of Arthroplasty*. 2025 Jan 1;40(1):203-7.
38. Patel I, Nham F, Zalikha AK, El-Othmani MM. Epidemiology of total hip arthroplasty: demographics, comorbidities and outcomes. *Arthroplasty*. 2023 Jan 3;5(1):2. <https://doi.org/10.1186/s42836-022-00156-1>
39. Fontalis A, Epinette JA, Thaler M, Zagra L, Khanduja V, Haddad FS. Advances and innovations in total hip arthroplasty. *SICOT-J*. 2021;7. PMID: PMC8040589 PMID: 33843582
40. Tokgöz E. Preexisting conditions leading to total hip arthroplasty. In *Total hip arthroplasty: Medical and biomedical engineering and science*

concepts 2022 Oct 20 (pp. 25-43). Cham: Springer International Publishing.

# Clinical Guideline Revision History/Information

Original Date: May 27, 2024		
Review History		
Version 2	6/10/2024	422.101 Disclaimer added
Version 3	2/20/2025	<p>Annual policy review &amp; restructure:</p> <ul style="list-style-type: none"> <li>● Improved and expanded references.</li> <li>● Updated recommended clinical approach to the current format.</li> <li>● Medical evidence section and references updated to reflect the current literature and professional society guidelines.</li> <li>● Updated conservative care language to better reflect current standard language</li> <li>● Reordered indications to place total hip arthroplasty first</li> <li>● Conservative management criteria reorganized to better align with CMS guidance.</li> <li>● Fracture indications for THA expanded - not more stringent than CMS. Revision indications expanded - not more stringent than CMS.</li> <li>● Defined clinical scenarios where nonsurgical management would be harmful or ineffective - not more stringent than CMS.</li> <li>● Conservative care language modified to reflect non-opioid pain control.</li> <li>● Modified steroid injection language for clarity.</li> </ul>
Version 3.1	3/21/2025	<ul style="list-style-type: none"> <li>● Updated policy per CMS revisions for 2/28/25</li> <li>● Updated Effective date</li> <li>● Updated Links and Bookmarks</li> </ul>